DCT

2:26-cv-11301

Takeda Pharma USA Inc v. Alvotech HF

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 2:26-cv-11301, D.N.J., 09/29/2026
  • Venue Allegations: Venue is alleged to be proper as to Alvotech, a foreign corporation, which subjects it to suit in any U.S. judicial district. The complaint also alleges Alvotech has transacted business in New Jersey and will commit acts of patent infringement in the district.
  • Core Dispute: Plaintiff alleges that Defendant’s submission of abbreviated Biologics License Applications (aBLAs) for proposed biosimilar versions of Plaintiff's ENTYVIO® product constitutes an act of patent infringement and that the future commercialization of these biosimilars will infringe seven U.S. patents covering methods of treating inflammatory bowel disease with the biologic vedolizumab.
  • Technical Context: The technology relates to vedolizumab (ENTYVIO®), a humanized monoclonal antibody used to treat inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease, which functions by selectively targeting the α4β7 integrin pathway in the gastrointestinal tract.
  • Key Procedural History: The action arises under the Biologics Price Competition and Innovation Act (BPCIA) following Defendant's submission of two aBLAs to the FDA seeking approval to market biosimilar versions of Plaintiff’s ENTYVIO® product for intravenous and subcutaneous administration. Plaintiff alleges Defendant failed to provide the required confidential access to its aBLAs, triggering a statutory right to bring a declaratory judgment action for patent infringement.

Case Timeline

Date Event
2011-05-02 Priority Date for all Asserted Patents
2014-05-01 FDA approves ENTYVIO® for intravenous use
2017-05-30 U.S. Patent No. 9,663,579 issues
2018-06-26 U.S. Patent No. 10,004,808 issues
2020-08-05 Alvotech and Teva Switzerland enter into license and development agreement
2023-09-01 FDA approves ENTYVIO® for subcutaneous use (UC)
2024-04-01 FDA approves ENTYVIO® for subcutaneous use (CD)
2024-05-29 Alvotech initiates Phase I clinical trial for AVT16
2024-08-06 U.S. Patent No. 12,053,526 issues
2024-09-01 Alvotech initiates confirmatory patient study for AVT16
2024-11-06 Alvotech concludes Phase I clinical trial for AVT16
2024-12-24 U.S. Patent No. 12,171,832 issues
2025-02-11 Alvotech initiates Phase I clinical trial for AVT80
2025-04-29 U.S. Patent No. 12,286,479 issues
2025-11-25 Alvotech's Phase III AVT16 study is terminated
2026-01-08 Alvotech concludes Phase I clinical trial for AVT80
2026-02-05 Alvotech announces positive top-line results for AVT80 PK study
2026-02-10 U.S. Patent No. 12,544,445 issues
2026-05-12 U.S. Patent No. 12,622,969 issues
2026-06-08 Alvotech announces FDA acceptance of aBLA for AVT16 (IV aBLA)
2026-06-15 Alvotech USA notifies Takeda of IV aBLA submission
2026-08-31 Alvotech announces FDA acceptance of aBLA for AVT80 (SC aBLA)
2026-09-17 Alvotech USA notifies Takeda of SC aBLA submission
2026-09-18 Alvotech USA provides Notice of Commercial Marketing for IV aBLA Product
2026-09-29 Amended Complaint is filed
2027-03-17 Expected commercial launch of Alvotech's IV aBLA Product

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,663,579 - “Formulation for anti-a4B7 Antibody,” issued May 30, 2017

The Invention Explained

  • Problem Addressed: The complaint states that early formulations of vedolizumab, the active ingredient, produced high rates of human anti-human antibodies (HAHA), also called anti-drug antibodies, which reduced the drug's efficacy in some patients Compl. ¶32 This problem of immunogenicity limited the drug's therapeutic potential.
  • The Patented Solution: The invention claims a specific method for treating Crohn's disease (CD) using an anti-α4β7 antibody Compl. ¶83 The solution is a multi-dose intravenous (IV) dosing regimen—a 300 mg first dose, a 300 mg second dose two weeks later, and a 300 mg third dose six weeks after the first dose—for patients who have not responded to or were intolerant to TNFα antagonists Compl. ¶83, claim 1 This regimen was discovered to dramatically reduce the immunogenicity issues seen in earlier studies, dropping HAHA rates from approximately 40% to about 4% Compl. ¶32 The patent also claims the specific heavy and light chain variable region sequences of the antibody Compl. ¶83, claim 1
  • Technical Importance: This specific dosing regimen solved a critical immunogenicity problem, enabling vedolizumab to become a successful long-term therapy for IBD and transforming its treatment paradigm (Compl. ¶¶1; Compl. ¶32).

Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶83
  • The essential elements of claim 1 are:
    • A method for achieving clinical response of Crohn's disease in a human patient with the disease who had a lack of adequate response with, lost response to, or was intolerant to a TNFα antagonist;
    • Comprising intravenously administering a specific antibody in a three-dose induction regimen: a 300 mg first dose, a 300 mg second dose two weeks later, and a 300 mg third dose six weeks later;
    • Wherein the antibody has binding specificity for human α4β7 integrin; and
    • Wherein the antibody comprises a heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2 and a light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 10,004,808 - “Methods of Treating Ulcerative Colitis,” issued June 26, 2018

The Invention Explained

  • Problem Addressed: The patent background describes an "urgent need to discover suitable dosages and dosing schedules" for anti-α4β7 antibodies for treating inflammatory bowel diseases, particularly formulations that can provide steady, therapeutically effective blood levels in a stable and convenient form (’808 Patent, col. 2:38-44).
  • The Patented Solution: The patent claims a method for inducing clinical remission of ulcerative colitis (UC) in patients who have failed or are intolerant to TNFα antagonist therapy ’808 Patent, abstract ’808 Patent, claim 1 The solution is a specific multi-dose IV regimen: an induction phase of 300 mg at weeks 0, 2, and 6, followed by a maintenance phase of 300 mg every eight weeks thereafter ’808 Patent, claim 1 This regimen is described as safe, easy to follow, and resulting in a therapeutically effective amount of the antibody in vivo ’808 Patent, abstract
  • Technical Importance: This invention provided a defined, clinically-supported treatment protocol for a difficult-to-treat patient population (TNFα antagonist failures), addressing a significant unmet medical need for UC therapies Compl. ¶5

Key Claims at a Glance

  • The complaint asserts independent claim 1 Compl. ¶107
  • The essential elements of claim 1 are:
    • A method for inducing clinical remission in a human patient with moderately to severely active ulcerative colitis who had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist;
    • Comprising intravenously administering an antibody in a multi-phase regimen: a 300 mg first dose, a 300 mg second dose two weeks later, a 300 mg third dose six weeks later, and then 300 mg every eight weeks thereafter;
    • Wherein the antibody has binding specificity for human α4β7 integrin; and
    • Wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2 and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

Multi-Patent Capsule: U.S. Patent No. 12,053,526

  • Patent Identification: U.S. Patent No. 12,053,526, “Methods for Treatment Using anti-alpha4beta7 Antibody,” issued August 6, 2024 Compl. ¶77
  • Technology Synopsis: The patent is directed to methods for treating a patient with ulcerative colitis (UC) Compl. ¶131 It claims a specific multi-dose IV dosing regimen that induces clinical response and remission, induces tolerance to the antibody, and results in a low HAHA titer, indicating reduced immunogenicity Compl. ¶131, claim 7
  • Asserted Claims: The complaint asserts at least representative independent claim 7 Compl. ¶131
  • Accused Features: The allegations concern Alvotech's IV aBLA Product, which is alleged to be administered according to the claimed dosing regimen to treat UC, thereby inducing clinical response, remission, and tolerance while producing a low HAHA titer Compl. ¶¶132-134 Compl. ¶¶138-139

Multi-Patent Capsule: U.S. Patent No. 12,171,832

  • Patent Identification: U.S. Patent No. 12,171,832, “Methods of Treating Ulcerative Colitis,” issued December 24, 2024 Compl. ¶78
  • Technology Synopsis: The patent is directed to a method of treating UC patients who have had an inadequate response to azathioprine or 6-mercaptopurine Compl. ¶157, claim 1 It claims a specific IV dosing regimen that achieves clinical response at 6 weeks and clinical remission at 52 weeks in this patient population Compl. ¶157, claim 1
  • Asserted Claims: The complaint asserts at least representative independent claim 1 (Compl. ¶157).
  • Accused Features: The allegations target Alvotech's IV aBLA Product. The complaint alleges that the product will be labeled for and used in the claimed dosing regimen to treat UC patients who have failed immunomodulator therapy, achieving the claimed clinical outcomes Compl. ¶¶158-162

Multi-Patent Capsule: U.S. Patent No. 12,544,445

  • Patent Identification: U.S. Patent No. 12,544,445, “Methods for Treatment Using anti-a4B7 Antibody,” issued February 10, 2026 Compl. ¶79
  • Technology Synopsis: The patent is directed to methods for treating IBD (CD or UC) with a two-phase (induction and maintenance) IV dosing regimen Compl. ¶182, claim 1 A key feature is achieving a specific mean trough serum concentration of the antibody (20 µg/ml to 30 µg/ml) at the end of the induction phase Compl. ¶182, claim 1
  • Asserted Claims: The complaint asserts at least representative independent claim 1 (Compl. ¶182).
  • Accused Features: The allegations concern Alvotech's IV aBLA Product, which is alleged to be administered according to the claimed dosing regimen to treat IBD and will produce the claimed trough serum concentration Compl. ¶¶183-187

Multi-Patent Capsule: U.S. Patent No. 12,622,969

  • Patent Identification: U.S. Patent No. 12,622,969, “Methods for Treatment Using anti-a4B7 Antibody,” issued May 12, 2026 Compl. ¶80
  • Technology Synopsis: This patent is directed to a method for treating IBD and minimizing the formation of human antihuman antibodies (HAHA) Compl. ¶207, claim 1 It claims a specific two-phase IV dosing regimen that results in at least 80% of patients being maintained as HAHA-negative for at least 6 weeks Compl. ¶207, claim 1
  • Asserted Claims: The complaint asserts at least representative independent claim 1 (Compl. ¶207).
  • Accused Features: The allegations concern Alvotech's IV aBLA Product. The complaint alleges its use will follow the claimed regimen and achieve the claimed outcome of maintaining at least 80% of patients as HAHA-negative Compl. ¶¶208-212

Multi-Patent Capsule: U.S. Patent No. 12,286,479

  • Patent Identification: U.S. Patent No. 12,286,479, “Treatment With Anti-a4B7 Antibody,” issued April 29, 2025 Compl. ¶81
  • Technology Synopsis: The patent is directed to a method for treating IBD that combines intravenous and subcutaneous administration Compl. ¶232, claim 1 It claims an induction phase with two IV doses followed by a maintenance phase of subcutaneous doses via a prefilled syringe or autoinjector Compl. ¶232, claim 1
  • Asserted Claims: The complaint asserts at least representative independent claim 1 (Compl. ¶232).
  • Accused Features: The allegations target Alvotech's SC aBLA Product (AVT80), which the complaint alleges will be used according to the claimed combination IV/SC dosing regimen to treat IBD and achieve clinical remission Compl. ¶¶233-236

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are Alvotech’s proposed biosimilar products AVT16 and AVT80, referred to in the complaint as the "IV aBLA Product" and the "SC aBLA Product," respectively (Compl. ¶¶8; Compl. ¶¶10; Compl. ¶14).

Functionality and Market Context

  • The accused products are described as proposed "interchangeable biosimilars" to Takeda’s ENTYVIO® product, a biologic medicine whose active ingredient is vedolizumab (Compl. ¶¶1; Compl. ¶9; Compl. ¶13). As biosimilars, the products are alleged to be "highly similar in [their] physical and biological characteristics" to ENTYVIO® (Compl. ¶12).
  • The IV aBLA Product (AVT16) is a vedolizumab injection for intravenous use in 300 mg single-use vials Compl. ¶10 The SC aBLA Product (AVT80) is a vedolizumab formulation for subcutaneous use in a 108 mg prefilled syringe and autoinjector Compl. ¶14
  • The complaint alleges that Alvotech seeks to "capitalize on Takeda's innovation" by marketing these biosimilars in partnership with Teva Pharmaceuticals International GmbH Compl. ¶8 Alvotech is alleged to be responsible for development and manufacturing, while Teva is responsible for commercialization Compl. ¶13 The complaint alleges an intent to launch the IV product as early as March 2027 (Compl. ¶52).

IV. Analysis of Infringement Allegations

The complaint includes a screenshot of the ENTYVIO® label showing the recommended dosing regimen for both intravenous and subcutaneous use, which underpins the infringement allegations for all asserted patents (Compl. ¶38).

U.S. Patent No. 9,663,579 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for achieving clinical response of Crohn's disease in a human patient...wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist: Alvotech's IV aBLA Product will be promoted for use in this patient population, as evidenced by Alvotech's clinical trials that sought out such subjects. ¶89 col. 28:50-55
a first dose of 300 mg of an antibody that has binding specificity for human a4β7 integrin, The IV aBLA Product will allegedly be administered as a 300 mg dose at week 0, consistent with the ENTYVIO® label. The antibody is vedolizumab, which binds to human α4β7 integrin. ¶86; ¶87 col. 4:10-14
a second dose of 300 mg of the antibody two weeks after the first dose, The IV aBLA Product will allegedly be administered as a 300 mg dose at week 2. ¶86 col. 4:14-17
and a third dose of 300 mg of the antibody six weeks after the first dose, The IV aBLA Product will allegedly be administered as a 300 mg dose at week 6. ¶86 col. 4:17-20
wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4. The active ingredient in the IV aBLA Product is alleged to have the same heavy and light chain variable regions as ENTYVIO®, which correspond to the claimed sequences. ¶88 col. 5:1-14

U.S. Patent No. 10,004,808 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for inducing clinical remission in a human patient having moderately to severely active ulcerative colitis... and wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist. Alvotech's IV aBLA Product will be promoted for use in UC patients who have failed TNFα antagonist therapy, as allegedly shown by Alvotech's clinical trials assessing this outcome. ¶108; ¶113 col. 28:20-27
comprising intravenously administering: a first dose of 300 mg of an antibody that has binding specificity for human a4β7 integrin, The IV aBLA Product allegedly will be administered as a 300 mg dose at week 0. The antibody is vedolizumab, which binds to human α4β7 integrin. ¶110; ¶111 col. 28:20-23
a second dose of 300 mg of the antibody two weeks after the first dose, The IV aBLA Product allegedly will be administered as a 300 mg dose at week 2. ¶110 col. 28:23-24
a third dose of 300 mg of the antibody six weeks after the first dose, The IV aBLA Product allegedly will be administered as a 300 mg dose at week 6. ¶110 col. 28:24-25
and then 300 mg of the antibody every eight weeks thereafter, The IV aBLA Product allegedly will be administered as a 300 mg dose every eight weeks thereafter as a maintenance therapy. ¶110 col. 28:25-27
wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4... The active ingredient in the IV aBLA Product is alleged to have the same heavy and light chain variable regions as ENTYVIO®, which correspond to the claimed sequences. ¶112 col. 5:1-14

Identified Points of Contention

  • Evidentiary Questions: The complaint's allegations are largely made "on information and belief," predicated on the accused products being interchangeable biosimilars of ENTYVIO®. A central question for the court will be whether the evidence from Alvotech's aBLA, once produced in discovery, confirms that the proposed product label will instruct for use in a manner that meets every limitation of the asserted method claims.
  • Scope Questions: The claims are highly specific, reciting exact dosages (300 mg or 108 mg), administration schedules (e.g., weeks 0, 2, 6), and antibody sequences (SEQ ID NOs). This specificity raises the question of whether Alvotech's products and proposed labeling will fall squarely within the literal scope of every limitation, or if minor deviations could necessitate an analysis under the doctrine of equivalents.

V. Key Claim Terms for Construction

  • The Term: "a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist" (appears in claim 1 of the ’579 and ’808 patents).
  • Context and Importance: This term defines a key patient population for the patented methods. The infringement allegations rely on Alvotech's proposed label instructing use in this exact population, and Alvotech's clinical trials allegedly targeted these patients (Compl. ¶¶89; Compl. ¶113). The construction of what constitutes an "inadequate response," "lost response," or "intolerance" will therefore be critical to determining the scope of the claims and whether the accused product's intended use infringes.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification of the ’808 patent does not appear to provide a specific, limiting definition of the term. The patent discusses clinical trials involving patients who had "failed prior therapies" generally (’808 Patent, col. 20:10-14). A party might argue this supports a broad construction encompassing a physician’s general clinical judgment that a TNFα antagonist is no longer suitable for a patient.
    • Evidence for a Narrower Interpretation: The detailed description of the GEMINI Phase III clinical trials mentions inducing and maintaining remission in patients who had failed prior therapies ’808 Patent, col. 10:2-6 A party could argue that the term should be limited to the specific criteria for "failure" or "inadequate response" used in the clinical trials that supported the patent, potentially narrowing the scope to patients meeting those exact criteria.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement for all asserted patents. The basis for inducement is the allegation that Alvotech, through its product labeling and promotional activities, will actively encourage and instruct healthcare providers and patients to use the biosimilar products in accordance with the patented methods Compl. ¶¶92; Compl. ¶116; Compl. ¶142; Compl. ¶167; Compl. ¶192; Compl. ¶217; Compl. ¶241
  • Willful Infringement: The complaint alleges that Alvotech "knows and is aware" of the asserted patents, including due to the filing of the original complaint Compl. ¶¶93; Compl. ¶117; Compl. ¶143; Compl. ¶168; Compl. ¶193; Compl. ¶218; Compl. ¶242 This forms the basis for a claim of willful infringement based on knowledge acquired, at the latest, upon service of the original complaint.

VII. Analyst’s Conclusion: Key Questions for the Case

  • A primary issue will be one of evidentiary proof: As this BPCIA case was filed prior to Takeda's receipt of Alvotech's confidential aBLA information, a central question is whether discovery will confirm Takeda's "information and belief" allegations. Will the final proposed product labels for AVT16 and AVT80 contain instructions for use that read directly on the specific patient populations, dosing amounts, and administration schedules recited in the asserted method claims?
  • A second key issue will concern procedural conduct under the BPCIA: The complaint alleges that Alvotech failed to comply with the "patent dance" provisions by not providing its aBLA materials as required by statute. The court's determination of whether this failure occurred and the legal consequences of such a failure could significantly shape the strategic options and remedies available to both parties throughout the litigation.
  • A third question relates to definitional scope: The case may turn on the construction of the patient population described in the claims, specifically what constitutes "a lack of an adequate response with, lost response to, or was intolerant to a TNFα antagonist." The court's interpretation of this phrase—whether it encompasses broad clinical judgment or is limited to specific criteria from clinical trials—will be pivotal in defining the scope of infringement.